BPA
VYNE icon

Beacon Pointe Advisors’s VYNE Therapeutics VYNE Stock Holding History

Beacon Pointe Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,111
Closed -$11.1K – 1198
2022
Q4 		$11.1K Sell
4,111
-56
-1% -$224 ﹤0.01% 1057
2022
Q3 		$17K Hold
4,167
– – ﹤0.01% 990
2022
Q2 		$28K Hold
4,167
– – ﹤0.01% 1031
2022
Q1 		$49K Buy
+4,167
New +$49.5K ﹤0.01% 1174
2021
Q4 		– Sell
-889
Closed -$22K – 1014
2021
Q3 		$22K Buy
889
+189
+27% +$7.33K ﹤0.01% 893
2021
Q2 		$44K Buy
700
+20
+3% +$1.58K ﹤0.01% 823
2021
Q1 		$83K Buy
680
+52
+8% +$7.54K 0.01% 521
2020
Q4 		$72K Sell
628
-129
-17% -$16.2K ﹤0.01% 498
2020
Q3 		$90K Sell
757
-581
-43% -$67.8K 0.01% 392
2020
Q2 		$166K Buy
+1,338
New +$181K 0.02% 383

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Beacon Pointe Advisors's VYNE Position: Q1 2023 in Review

Beacon Pointe Advisors sold out of VYNE Therapeutics (VYNE) in Q1 2023, closing a stake of 4,111 shares — an estimated $11.1K sold.

Beacon Pointe Advisors first reported a position in VYNE in Q2 2020 and held it in 10 quarters. The position peaked at $166K in Q2 2020. 23 funds tracked by Wall St. Rank hold VYNE as of Q1 2023.

  • Beacon Pointe Advisors reported no remaining VYNE Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Beacon Pointe Advisors sold 4,111 VYNE Therapeutics shares in Q1 2023, an estimated $11.1K.
  • Beacon Pointe Advisors first reported a position in VYNE Therapeutics in Q2 2020 and held it in 10 quarters.
  • Beacon Pointe Advisors's VYNE Therapeutics position peaked at $166K in Q2 2020.
  • 23 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2023.

Based on Beacon Pointe Advisors's 13F filing for Q1 2023, filed 12 May 2023.